Get Quote
Home Products About Us Contact Verification Get Quote

Cagrilintide + Semaglutide Blend (CagriSema)

≥99% Purity
Fast Shipping
COA Included
New

Categories: GLP-1 Agonists, Peptide Blends

CagriSema research blend: Cagrilintide (amylin) + Semaglutide (GLP-1) — dual-pathway metabolic combination targeting distinct neuronal satiety populations for next-generation obesity and metabolic research.


The Cagrilintide + Semaglutide Blend (CagriSema research analog) combines two peptides that target distinct but complementary satiety and metabolic signaling pathways. Cagrilintide, a long-acting acylated amylin analog, activates amylin receptors (AMY1/2/3) in the area postrema and nucleus tractus solitarius of the brainstem — the primary central integration site for meal-related satiety signals. Semaglutide, a GLP-1 receptor agonist with C18 fatty acid acylation for albumin binding, acts on GLP-1R-expressing neurons in the hypothalamic arcuate nucleus, paraventricular nucleus, and lateral hypothalamic area, as well as hindbrain GLP-1R populations.

The synergy rationale is grounded in neuroanatomy: amylin and GLP-1 signaling converge on overlapping but non-identical neuronal populations within the brainstem and hypothalamus. Published research indicates that concurrent activation of both pathways produces greater suppression of food intake and energy balance modulation than either pathway alone, because the two signals are processed by partially independent neural circuits that sum their effects at the level of behavioral output. This dual amylin/GLP-1 paradigm represents the leading edge of multi-agonist metabolic research.

Available in two configurations: 2.5mg + 2.5mg and 5mg + 5mg per vial. Co-lyophilized with ≥99% purity per component. Store at -20°C desiccated. For metabolic research only.

⚠ Supplied strictly for research and experimental purposes only.